Another mechanism by which CDK9 inhibition has been shown to increase anti-tumour immunity is by reactivating tumour suppressor genes that are important for cellular immune responses, which enhanced recruitment of immune cells to xenografts and sensitised a syngeneic ovarian cancer model to anti-PD-1 therapy [207]. This evidence concerns the gene CDK9 and neoplasm.